NicOx and TOPIGEN Pharmaceuticals terminate collaboration following the acquisition of TOPIGEN by Pharmaxis
14-Jan-2010 -
NicOx S.A. announced that NicOx and TOPIGEN Pharmaceuticals Inc. have mutually terminated their collaboration for TPI 1020. This decision was made as a result of the acquisition of TOPIGEN by Pharmaxis.
Following two phase 2a studies that were conducted by TOPIGEN with TPI 1020 in patients with ...
anti-inflammatory drugs
asthma